Advertisement Bioniche Pharma wins FDA approval for generic KetalarCIII - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bioniche Pharma wins FDA approval for generic KetalarCIII

Bioniche Pharma, a developer and manufacturer of injectable pharmaceuticals, has received the FDA approval for its 10mg/ml strength of ketamine hydrochloride injection, USP, the generic equivalent of JHP Pharmaceuticals's KetalarCIII.

The 10mg/ml strength joins Bioniche’s current offering of Ketamine in 50mg/ml and 100mg/ml strengths and completes its full product line offering. Bioniche plans to launch the 10mg/ml strength in October 2008.

Steve Thornton, CEO of Bioniche Pharma, said: “We are pleased to offer our customers a full line of ketamine for their treatment needs.”